<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-BIHKGE39/013c3978-790e-4a2b-82f1-0637d8e3ada5/PDF"><dcterms:extent>986 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-BIHKGE39/76f56eaa-055c-454f-bffc-824e035309c7/TEXT"><dcterms:extent>35 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-BIHKGE39"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2020</dcterms:issued><dc:creator>Kodrič, Ana</dc:creator><dc:creator>Kos, Mitja</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">letnik:71</dc:format><dc:format xml:lang="sl">str. 275-285</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:41228291</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-BIHKGE39</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">hipertenzija</dc:subject><dc:subject xml:lang="sl">Hipertenzivna srčna bolezen</dc:subject><dc:subject xml:lang="sl">Krvni tlak</dc:subject><dc:subject xml:lang="sl">odnos do zdravil</dc:subject><dc:subject xml:lang="sl">sodelovanje pri zdravljenju</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Odnos do zdravil in sodelovanje bolnikov s hipertenzijo pri zdravljenju z zdravili v Sloveniji| Medication beliefs and medication adherence in patients with hypertension in Slovenia|</dc:title><dc:description xml:lang="sl">We conducted a study in community pharmacies in Slovenia with the aim of evaluating the hypertensive patients' medication beliefs and their impact on medication adherence and blood pressure control. Medication beliefs were evaluated by Beliefs about Medicines Questionnaire, and medication adherence was evaluated by pill count. A total of 117 patients were enrolled in the study. 30.2% of patients do not recognise the need to take blood pressure lowering medicines and in 12.9% of patients, concerns about taking them outweigh the perception of benefits. 3.4% of patients are sceptical, 11.2% ambivalent, 26.7% indifferent and 58.6% are accepting regarding their blood pressure lowering therapy. Medication beliefs have an impact on medication adherence, since patients who are concerned about taking antihypertensive medications are less likely to take them regularly. Medication adherence is 16.5% higher in accepting patients nd 18.7% higher in indifferent patients than in ambivalent patients. Results also indicate the impact of medication beliefs on blood pressure control in patients with hypertension</dc:description><dc:description xml:lang="sl">V zunanjih lekarnah po Sloveniji smo izvedli raziskavo, s katero smo želeli ovrednotiti odnos do zdravil pri bolnikih s hipertenzijo in vpliv le-tega na sodelovanje pri zdravljenju in krvni tlak. Odnos smo ovrednotili z vprašalnikom Beliefs about Medicines Questionnaire, sodelovanje pri zdravljenju pa s štetjem osnovnih enot zdravila. V raziskavo je bilo vključenih 117 bolnikov. Med njimi jih 30,2 % ne prepoznava potrebe po jemanju zdravil za zniževanje krvnega tlaka in pri 12,9 % zaskrbljenost zaradi jemanja prevlada nad dojemanjem njihovih koristi. Glede antihipertenzivne terapije je skeptičnih 3,4 %, ambivalentnih 11,2 %, indiferentnih 26,7 % in sprejemajočih 58,6 %. Odnos do zdravil vpliva na sodelovanje pri zdravljenju z antihipertenzivi, saj bolniki, ki so glede jemanja zdravil zaskrbljeni, le-ta jemljejo manj redno. Sodelovanje je pri sprejemajočih za 16,5 % večje, pri indiferentnih pa za 18,7 % večje kot pri ambivalentnih bolnikih. Rezultati nakazujejo tudi na vpliv odnosa na urejenost krvnega tlaka pri bolnikih s hipertenzijo</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-BIHKGE39"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-BIHKGE39" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-BIHKGE39/013c3978-790e-4a2b-82f1-0637d8e3ada5/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-BIHKGE39/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-BIHKGE39" /></ore:Aggregation></rdf:RDF>